<DOC>
	<DOCNO>NCT00020462</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's cancer cell may make body build immune response kill tumor cell . Combining vaccine therapy interleukin-2 may effective treatment follicular lymphoma . PURPOSE : Phase I trial study effectiveness vaccine therapy plus interleukin-2 treating patient stage III , stage IV , recurrent follicular lymphoma .</brief_summary>
	<brief_title>Vaccine Therapy Plus Interleukin-2 Treating Patients With Stage III , Stage IV , Recurrent Follicular Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess safety immunotherapy autologous tumor cell vaccine interleukin-2 patient stage III , IV , recurrent follicular lymphoma . - Determine clinical response patient treat regimen . - Assess immune response patient treat vaccine . OUTLINE : This multicenter study . Patients stratify accord prior therapy ( prior biologic therapy chemotherapy lymphoma v prior prednisone , doxorubicin , cyclophosphamide , etoposide ( PACE ) chemotherapy ) . Patients without prior therapy stratify accord accessibility lymph node ( easily accessible ( stratum Ia ) vs easily accessible ( stratum Ib ) ) . All patient undergo lymph node biopsy obtain tissue vaccine manufacture . Treatment begin approximately 1 month biopsy . - Stratum Ia : Patients receive autologous tumor cell vaccine interleukin-2 ( IL-2 ) intranodally subcutaneously ( SC ) day 1 . - Stratum Ib stratum II : Patients receive autologous tumor cell vaccine IL-2 SC day 1 . Treatment stratum continue every 4 week maximum 5 course absence disease progression unacceptable toxicity . Patients follow 1 4 month , every 3 month 1 year , every 6 month thereafter relapse progression disease . PROJECTED ACCRUAL : A total 20 patient ( 10 per stratum ) accrue study within 1.5-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven follicular center cell lymphoma surface immunoglobulin ( Ig ) M , G , A phenotype Grade I ( follicular small cleave cell ) Grade II ( follicular mix small large cell ) Grade III ( follicular large cell ) Stage III , IV , recurrent disease Previously untreated chemotherapy monoclonal antibody therapy OR Recurrent , residual disease progressive disease prior prednisone , doxorubicin , cyclophosphamide , etoposide ( PACE ) chemotherapy Peripheral lymph node least 2 cm accessible biopsy/harvest No primary secondary CNS lymphoma Must following : Rapidly progress lymphadenopathy Bone marrow failure secondary lymphoma B symptom Neurovascular organ compromise secondary lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : More 1 year Hematopoietic : Not specify Hepatic : ALT/AST great 3.5 time upper limit normal Bilirubin great 1.5 mg/dL unless secondary Gilbert 's disease Hepatitis B surface antigen negative Hepatitis C antibody negative Renal : Creatinine great 1.5 mg/dL Other : HIV negative No active infection No prior concurrent malignancy except curatively treat squamous cell basal cell skin cancer effectively treat carcinoma situ cervix No medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent biologic therapy lymphoma Chemotherapy : See Disease Characteristics At least 3 month since prior PACE chemotherapy No concurrent chemotherapy Endocrine therapy : At least 2 week since prior steroid treatment Less 2 month prior prednisone No concurrent endocrine therapy lymphoma Radiotherapy : Prior radiotherapy 1 site allow At least 2 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Lymph node biopsy perform within past month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>